SCHEMBL4239186

SCHEMBL4239186

COc1ccc(CNC(=O)c2cccc3nc(C(N)=O)[nH]c23)cc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 5/20 0.50
MAPT P10636 4/20 0.50
LMNA P02545 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
MMP13 P45452 2/20 0.48
ALDH1A1 P00352 1/20 0.48
CD38 P28907 1/20 0.48
EGLN1 Q9GZT9 1/20 0.47
UBE2I P63279 1/20 0.47
CACNA1B Q00975 1/20 0.47
APBA1 Q02410 1/20 0.47
SAE1 Q9UBE0 1/20 0.47
UBA2 Q9UBT2 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
TP53 P04637 1/20 0.46
RXFP1 Q9HBX9 1/20 0.46
HDAC1 Q13547 1/20 0.46
ABCG2 Q9UNQ0 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4247241 0.90 ABCG2 (0.56) MAPTLMNAALDH1A1EGLN1UBE2I
SCHEMBL4246321 0.90 HPGD (0.58) HPGDMMP13ALDH1A1KMT2A
SCHEMBL4239339 0.88 HPGD (0.52) HPGDMAPTLMNAALDH1A1KMT2A
SCHEMBL4239188 0.87 HPGD (0.52) HPGDMAPTLMNASMN1; SMN2ALDH1A1
SCHEMBL4244271 0.87 HTR2C (0.49) MMP13EGLN1
SCHEMBL4239959 0.87 SMN1; SMN2 (0.53) HPGDMAPTLMNASMN1; SMN2KMT2A
SCHEMBL4246314 0.86 SMN1; SMN2 (0.50) MAPTLMNASMN1; SMN2ALDH1A1EGLN1
SCHEMBL4241582 0.86 POLA1 (0.46) HPGDLMNASMN1; SMN2ALDH1A1CD38
SCHEMBL4241181 0.84 KMT2A (0.54) ALDH1A1MEN1KMT2A
SCHEMBL4243626 0.84 MEN1 (0.51) MAPTLMNASMN1; SMN2ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8946259-B2 Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2015-02-03 US disclosed
US-20140066477-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2014-03-06 US disclosed
US-8598353-B2 Benzazole derivatives, compositions, and methods of use as β-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC (US) 2013-12-03 US disclosed
US-20090326006-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors VTVX HOLDINGS II LLC 2009-12-31 US disclosed
US-20060223849-A1 Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors HIGH POINT PHARMACEUTICALS, LLC 2006-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326006-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors BACE1, BACE2, APP HPGD 1702/4885MAPT 85/4885LMNA 679/4885
US-20060223849-A1 Benzazole derivatives, compositions, and methods of use as beta-secretase inhibitors BACE1, BACE2, APP HPGD 1702/4885MAPT 85/4885LMNA 679/4885
US-20140066477-A1 Benzazole Derivatives, Compositions, and Methods of Use as Beta-Secretase Inhibitors BACE1, BACE2, APP HPGD 1702/4885MAPT 85/4885LMNA 679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.